3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
8
Neoplasms
4
Thrombosis
3
Pulmonary Embolism
3
Venous Thrombosis
2
Multiple Myeloma
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Ovarian Neoplasms
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Endometrial Neoplasms
1
Catheter-Related Infections
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Temozolomide
10
Specimen Handling
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Bevacizumab
3
trametinib
2
Surgical Procedures, Operative
2
Radiation
2
Magnetic Resonance Imaging
2
Leukapheresis
2
Genetic Therapy
2
Fluorodeoxyglucose F18
2
Biopsy
2
vorasidenib
1
trastuzumab deruxtecan
1
ribociclib
1
regorafenib
1
olutasidenib
1
mirdametinib
1
lorlatinib
1
dabrafenib
1
apixaban
1
aflibercept
1
abexinostat
1
Vinblastine
1
Tretinoin
1
Therapies, Investigational
1
Restraint, Physical
1
Re-Irradiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Astrocytoma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled